百特醫療 (BAX) 2017 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to Baxter International's Fourth Quarter 2017 Earnings Conference Call. (Operator Instructions) As a reminder, this call is being recorded by Baxter and is copyrighted materials. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objection, please disconnect at this time.

    各位女士、先生,早安,歡迎參加百特國際(Baxter International)2017 年第四季財報電話會議。(接線員指示)提醒各位,本通話由百特錄音並受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請於此時中斷連線。

  • I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.

    現在我想把電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,您可以開始。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Thanks, Candace. Good morning and welcome to our fourth quarter 2017 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.

    謝謝你,Candace。早安,歡迎參加我們 2017 年第四季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。

  • On the call this morning, we will be discussing Baxter's fourth quarter 2017 financial results, along with our financial outlook for 2018. As a reminder, we have posted a supplemental presentation to complement this morning's discussion. This presentation, along with the related non-GAAP reconciliations, can be accessed on Baxter's external website in the Investors section under Events & Presentations.

    今天早上的電話會議中,我們將討論百特 2017 年第四季財務結果,以及我們對 2018 年的財務展望。提醒各位,我們已發布補充簡報以配合今天早上的討論。該簡報以及相關的非 GAAP 調節表,可於百特對外網站的投資人專區,在「活動與簡報(Events & Presentations)」項下取得。

  • As previously mentioned, we've reorganized our commercial structure to boost performance, optimize costs, increase speed in the decision-making process and drive improved accountability across Baxter. To that end, we will be modifying how we report our quarterly financial sales and segment analysis. This new structure will reflect the current makeup of our commercial operation. And while we recognize these changes will impact your models, we believe this presentation will provide you with more granularity regarding our top line performance by global business units and regions.

    如先前所提,我們已重整商業組織架構,以提升績效、最佳化成本、加快決策流程並強化百特全公司的責任歸屬。因此,我們將調整季度財務銷售與部門分析的揭露方式。此新架構將反映我們商業營運目前的組成。雖然我們了解這些變更會影響各位的模型,但我們相信本簡報將就全球事業單位與區域別的營收表現,提供更細緻的資訊。

  • To aid you in this transition, this morning, we posted reclassified sales schedules for the global businesses for the last 3 years, inclusive of 2017. These schedules can be found in the Investors section of baxter.com. The regional segment structure will be included in our 10-K filing with the SEC.

    為協助各位順利銜接,今天早上我們已發布過去 3 年(含 2017 年)全球業務的重分類銷售明細表。這些明細表可在 baxter.com 的投資人專區找到。區域別部門架構將納入我們向美國證券交易委員會(SEC)提交的 10-K 年報。

  • With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, business development and regulatory matters contain forward-looking statements that involve risks and uncertainties. And of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.

    接下來,在開始我們的準備發言前,先提醒各位:本簡報(包含關於我們財務展望、新產品開發、業務開發及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。關於可能導致實際結果與預期有重大差異的因素,請參閱今日新聞稿及我們向 SEC 提交的文件以取得更多資訊。

  • In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.

    此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務的經營表現。今日所討論之非 GAAP 財務衡量指標與可比 GAAP 財務衡量指標的調節表,已收錄於我們今早發布並可於網站取得的財報新聞稿中。

  • Now I'd like to turn the call over to Joe.

    現在我想把電話交給 Joe。

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Good morning and thanks for joining us today. I will start with a brief look at our fourth quarter performance, then I will share some thoughts on 2017 as a whole and how we are well positioned to sustain this momentum into 2018 and beyond. Jay will then take a closer look at our 2017 financials and outlook for 2018. We'll close with Q&A.

    早安,感謝各位今天加入我們。我將先簡要回顧第四季表現,接著分享對 2017 年整體的看法,以及我們如何已做好準備,將這股動能延續至 2018 年及未來。之後 Jay 會更深入檢視我們 2017 年財務表現與 2018 年展望。最後我們將進行問答。

  • Baxter finished the year with another solid quarter, delivering fourth quarter sales growth of 5% on a reported basis, 3% on a constant currency basis and 2% operationally. Operational sales are adjusted for the impact of foreign exchange, generic competition for U.S. cyclophosphamide, the Claris acquisition and the previously communicated selected strategic product exits the company has undertaken.

    百特以另一個穩健的季度為今年畫下句點:第四季銷售額以報告基礎計成長 5%,以固定匯率基礎計成長 3%,以營運基礎計成長 2%。營運銷售額已調整外匯影響、美國環磷醯胺(cyclophosphamide)的學名藥競爭、Claris 併購案,以及公司先前已溝通之部分策略性產品退出所帶來的影響。

  • On the bottom line, adjusted earnings per share were $0.64, up 12% year-over-year, driven by strong operational performance, the ongoing impact of our business transformation efforts and a lower tax rate. This performance more than offset the impact in the quarter from Hurricane Maria, which reduced our results by approximately $70 million on the top line and approximately $0.06 on the bottom line.

    在獲利方面,調整後每股盈餘為 0.64 美元,年增 12%,主要受惠於強勁的營運表現、我們業務轉型措施的持續效益,以及較低的稅率。此表現不僅抵銷了瑪麗亞颶風在本季的影響;該颶風使我們營收約減少 7,000 萬美元,並使獲利端約減少 0.06 美元。

  • For full year 2017, Baxter achieved top line growth of 4% on a reported and constant currency basis and 5% operationally. Adjusted income from continuing operations of $2.48 per diluted share, an increase of 27% and free cash flow of more than $1.2 billion.

    2017 全年,百特營收以報告基礎與固定匯率基礎皆成長 4%,以營運基礎成長 5%。持續營運的調整後每股稀釋盈餘為 2.48 美元,成長 27%,自由現金流超過 12 億美元。

  • Before we discuss some key highlights for 2017, I wanted to take a moment to update you on our operations in Puerto Rico. We've been intently focused on addressing the supply situation in U.S. in the aftermath of the hurricane and the challenging impact it has had on our customers. Our primary goal, as always, is to ensure we can address the needs of patients and healthcare providers, and we have mobilized accordingly.

    在討論 2017 年幾項重點之前,我想先花點時間向各位更新我們在波多黎各的營運狀況。颶風過後,我們一直專注於解決美國的供應情況,以及其對客戶造成的嚴峻影響。我們的首要目標一如既往,是確保能滿足病患與醫療照護提供者的需求,並已據此動員資源。

  • All of our Puerto Rico facilities are now connected to the electrical grid, and we've been ramping up production to pre-hurricane levels. Our expectation is that we'll be able to return to more normal supply levels over the coming weeks. And as such, we expect the residual sales impact of approximately $25 million in the first quarter of 2018.

    我們在波多黎各的所有廠區目前都已接上電網,並正逐步將產能提升至颶風前水準。我們預期在未來幾週內可回到較正常的供應水準。因此,我們預期 2018 年第一季仍將有約 2,500 萬美元的剩餘營收影響。

  • In a related matter, as you are likely aware, an aggressive flu season in U.S. coupled with industry-wide supply challenges has heightened demand for Baxter's large volume IV solutions, which we produce outside of Puerto Rico. As I mentioned on our last earnings call, we have received permanent FDA approval to import large volume IV solutions from our plant in Cuernavaca, Mexico, to help address increased demands from our customers and potentially serve new customers in the future.

    相關地,各位可能也知道,美國流感季來勢洶洶,加上全產業供應挑戰,使百特的大容量靜脈輸液(IV solutions)需求升高;該產品由我們在波多黎各以外的地點生產。如我在上次財報電話會議所提,我們已取得 FDA 的永久核准,可自墨西哥庫埃納瓦卡(Cuernavaca)工廠進口大容量靜脈輸液,以協助因應客戶需求增加,並在未來可能服務新客戶。

  • Now turning to some 2017 highlights. The Claris acquisition represents an important example of our commitment to enhancing our portfolio and pipeline in our core growth businesses like generic injectable pharmaceuticals. We are rapidly integrating the Claris team, bringing this operations fully online with Baxter's quality systems and looking forward to continued momentum and commercial growth over the long term.

    接著談談 2017 年的一些重點。Claris 併購案是我們致力於強化核心成長業務(如學名注射劑藥品)之產品組合與研發管線的重要例證。我們正快速整合 Claris 團隊,使其營運全面導入百特的品質系統,並期待長期持續的動能與商業成長。

  • And earlier this year, we announced an agreement to acquire 2 hemostat and sealant products from Mallinckrodt, RECOTHROM and PREVELEAK, both compelling proposed additions to our advanced surgical portfolio.

    此外,今年稍早我們宣布與 Mallinckrodt 達成協議,收購兩項止血與封合產品 RECOTHROM 與 PREVELEAK;兩者皆是對我們先進外科產品組合具吸引力的擬議新增項目。

  • From an R&D perspective, we entered into some promising partnerships designed to augment our portfolio and potentially lead to transformative patient care technologies. Our organic R&D pipeline is also advancing with several high potential developments. In the U.S. market, we received FDA guidance clarifying the regulatory pathway for new home-based peritoneal dialysis or PD solution generation system that may allow even more patients to experience the benefits of home therapy. And we have initiated U.S. clinical trials of HDx therapy enabled by THERANOVA, a Baxter technology now available in many global markets that is designed to closely mimic the natural kidney through a clearance of certain molecules during dialysis.

    從研發角度來看,我們已建立一些前景可期的合作夥伴關係,旨在強化我們的產品組合,並有望帶來具變革性的病患照護技術。我們的內生研發管線也在推進中,包含數項高潛力的開發案。在美國市場,我們獲得 FDA 指引,釐清新型居家腹膜透析(peritoneal dialysis,PD)或 PD 溶液生成系統的法規途徑,這可能讓更多病患得以享受居家治療的益處。此外,我們已在美國啟動由 THERANOVA 所支援的 HDx 治療臨床試驗;THERANOVA 為百特(Baxter)技術,現已在多個全球市場上市,其設計旨在於透析過程中清除特定分子,以更貼近自然腎臟的功能。

  • Outside the U.S., we begin to limit launch of PrisMAX, our latest technology advanced for acute care therapies in Europe. We anticipate full European launch later this year. Also in acute therapies, we launched a label expansion for oXIRIS blood purification set in select markets outside the U.S. This marks the first 3-in-1 set for use in continuous renal replacement therapies or CRRT in sepsis management protocols.

    在美國以外,我們開始在歐洲有限度推出 PrisMAX,這是我們最新、用於急性照護治療的先進技術。我們預期將於今年稍晚在歐洲全面上市。同樣在急性治療領域,我們在美國以外的部分市場推出 oXIRIS 血液淨化組件的適應症標示擴增。這標誌著首款 3 合 1 組件,可用於連續性腎臟替代治療(continuous renal replacement therapies,CRRT)的敗血症管理流程。

  • We continue to advance customer focus enhancements for high-value technologies across our core portfolio, including our AK 98 hemodialysis system, our FLOSEAL and TISSEEL hemostatic agents and the SIGMA SPECTRUM infusion system. In 2017, also marked the 1 million PD treatment using our proprietary SHARESOURCE telemedicine technology. SHARESOURCE is foundational rather to the success of our newest automated PD cyclers, AMIA in the U.S. and HOMECHOICE CLARIA in international markets.

    我們持續推動核心產品組合中高價值技術的客戶導向強化措施,包括 AK 98 血液透析系統、FLOSEAL 與 TISSEEL 止血劑,以及 SIGMA SPECTRUM 輸注系統。2017 年也達成使用我們專有的 SHARESOURCE 遠距醫療技術進行第 100 萬次 PD 治療的里程碑。SHARESOURCE 是我們最新自動化 PD 透析機成功的基礎:美國市場的 AMIA,以及國際市場的 HOMECHOICE CLARIA。

  • Last week, we announced FDA approval of Bivalirudin, using Baxter's proprietary frozen GALAXY container technology, making it the first and only presentation of this generic cardiovascular injectable in a convenient frozen premixed solution.

    上週,我們宣布 Bivalirudin 獲得 FDA 核准,採用百特專有的冷凍 GALAXY 容器技術,使其成為此一學名藥心血管注射劑首款且唯一以便利的冷凍預混溶液形式提供的產品。

  • This internal and external investments designed to accelerate future growth are balanced, along with our commitment to return significant value to our shareholders. To this end, during 2017, we increased our annual dividend rate by 23%, while also repurchasing more than $560 million worth of shares.

    這些旨在加速未來成長的內外部投資,與我們致力於為股東回饋可觀價值的承諾相互平衡。為此,2017 年我們將年度股利率提高 23%,同時也回購了超過 5.6 億美元的股份。

  • Overall, we are energized by what we accomplished for our stakeholders in 2017. And it has all been made possible by our 47,000 employees globally, who are absolutely committed to our mission and the success of our transformation.

    整體而言,我們對 2017 年為利害關係人所達成的成果感到振奮。而這一切都得益於我們全球 47,000 名員工,他們對我們的使命以及轉型成功的承諾堅定不移。

  • As we look to our expectations for 2018, increased operational efficiency remains essential, and we will continue to identify opportunities to improve operating leverage. At the same time, we are intensely focused on accelerating top line performance. We know by enhancing our product mix, we can drive sustainable gross margin improvement for the company. As such, we will continue to ramp up our emphasis on new product innovation and business developments for this objective. We look forward to updating you on these strategic initiatives, particularly many of our existing and exciting pipeline programs at our upcoming investor conference on May 21 in New York City.

    展望 2018 年,我們預期提升營運效率仍至關重要,我們將持續尋找機會以改善營運槓桿。同時,我們也高度聚焦於加速營收成長表現。我們知道,透過優化產品組合,我們可以推動公司毛利率的可持續改善。因此,為達成此目標,我們將持續加大對新產品創新與業務發展的投入與重視。我們期待在 5 月 21 日於紐約市舉行的投資人會議上,向各位更新這些策略性舉措,特別是我們現有且令人振奮的多項管線計畫。

  • In summary, while we have a lot of hard work ahead, as we continue to position for the future, I'm confident that we are up to the task.

    總結而言,儘管前方仍有大量艱鉅工作,但在我們持續為未來布局之際,我有信心我們能勝任這項任務。

  • Now I'll pass it to Jay for a deeper dive on fourth quarter performance and outlook for 2018.

    接下來我將交給 Jay,請他更深入說明第四季的表現以及 2018 年展望。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Thanks, Joe, and good morning, everyone. As Joe mentioned, we're pleased with our fourth quarter results, which represented a strong finish to a great year. I'll start by discussing our fourth quarter and full year 2017 results before providing our financial outlook for 2018.

    謝謝你,Joe,各位早安。如 Joe 所提到的,我們對第四季的結果感到滿意,這為精彩的一年畫下強勁句點。在提供 2018 年財務展望之前,我將先討論我們第四季與 2017 全年的業績。

  • Beginning with the fourth quarter. Sales increased 5% on a reported basis, 3% at constant currency and 2% on an operational basis. Key growth drivers for the quarter included continued momentum across our U.S. Fluid Systems and Renal businesses as well as strength internationally in Nutrition and increased demand for our cytotoxic contract manufacturing services. As previously mentioned, disruptions to our Puerto Rico manufacturing facilities negatively impacted fourth quarter sales by approximately $70 million.

    先從第四季開始。銷售額以報告基礎成長 5%,以固定匯率計成長 3%,以營運基礎計成長 2%。本季主要成長動能包括:我們美國輸液系統與腎臟業務持續的成長動能、國際市場營養產品的強勁表現,以及對我們細胞毒性藥物委託製造服務需求的增加。如先前所提,波多黎各製造設施的中斷對第四季銷售造成負面影響,約為 7,000 萬美元。

  • On the bottom line, adjusted earnings increased 12% to $0.64 per diluted share. This exceeded our previous guidance of $0.56 to $0.59 per share driven by operational performance, disciplined management of expenses and a modest benefit from foreign exchange gains on balance sheet positions.

    在獲利方面,調整後盈餘成長 12%,至每股稀釋後 0.64 美元。此結果高於我們先前每股 0.56 至 0.59 美元的指引,主要受惠於營運表現、費用的紀律性管理,以及因資產負債表部位而產生的外匯收益所帶來的小幅助益。

  • Now I'll walk you through performance by business. I'll speak to growth figures on an operational basis to provide a clearer understanding of underlying performance. As a reminder, operational growth excludes the impact of foreign exchange, U.S. cyclophosphamide, Claris and select strategic product exits.

    接下來我將帶各位檢視各業務的表現。我將以營運基礎的成長數據進行說明,以更清楚呈現基本面表現。提醒各位,營運成長不包含外匯影響、美國 cyclophosphamide、Claris,以及部分策略性產品退出的影響。

  • Global sales for Hospital Products were $1.7 billion, advancing 1% operationally. Breaking this out by business, sales in Fluid Systems were $632 million, up 2% operationally. Performance was driven by strength for large volume IV solutions and IV access sets in the U.S. Growth in the quarter was offset by lower sales internationally and the impact from Hurricane Maria.

    醫院產品(Hospital Products)全球銷售額為 17 億美元,營運基礎成長 1%。按業務拆分,輸液系統(Fluid Systems)銷售額為 6.32 億美元,營運基礎成長 2%。表現主要由美國大容量靜脈輸液(IV)溶液與 IV 連接組件的強勁需求所帶動;但本季成長部分被國際市場較低的銷售以及瑪麗亞颶風的影響所抵銷。

  • Integrated Pharmacy Solutions or IPS. Sales were $602 million, flat to prior year on an operational basis. Sales growth in the quarter was negatively impacted by $56 million from Hurricane Maria, which offset increased sales of our premixed injectable drug in the U.S. and parenteral nutrition therapies internationally as well as strength in our hospital pharmacy compounding business. Sales of U.S. cyclo were $43 million in the quarter and Claris contributed $30 million globally.

    整合藥房解決方案(Integrated Pharmacy Solutions,IPS)。銷售額為 6.02 億美元,營運基礎與去年同期持平。本季銷售成長受到瑪麗亞颶風帶來的 5,600 萬美元負面影響,抵銷了我們在美國預混注射劑藥品銷售的增加、國際市場腸外營養治療的成長,以及醫院藥房調配業務的強勁表現。本季美國 cyclo 銷售額為 4,300 萬美元,Claris 在全球貢獻 3,000 萬美元。

  • Moving to surgical care, which includes anesthesia and advanced surgery. Total sales were $363 million, increasing 3% operationally. Growth in the quarter benefited from increased sales in inhaled anesthetics internationally and U.S. sales of BREVIBLOC. Also contributing to performance was growth in advanced surgery of 3%. Sequentially, advanced surgery grew 5% as we are beginning to recognize many of the actions we have implemented to improve performance in this business.

    接著是外科照護(surgical care),包含麻醉與先進外科。總銷售額為 3.63 億美元,營運基礎成長 3%。本季成長受惠於國際市場吸入式麻醉劑銷售增加,以及 BREVIBLOC 在美國的銷售。先進外科業務 3% 的成長也對表現有所貢獻。以季比來看,先進外科成長 5%,顯示我們為改善該業務表現所採取的多項措施正開始反映在成果上。

  • Fourth quarter surgical care growth was impacted by lower sales of Transderm Scop as a result of increased competition.

    第四季外科照護的成長受到 Transderm Scop 銷售下滑的影響,原因是競爭加劇。

  • Finally, in Hospital Products, sales in our other category were $108 million, increasing 1%, driven by favorable demand for the company's cytotoxic manufacturing services.

    最後,在醫院產品方面,我們其他類別的銷售額為1.08億美元,成長1%,主要受惠於市場對本公司細胞毒性藥物製造服務的需求增加。

  • Turning to our Renal business. Sales were approximately $1.1 billion, up 4% operationally. Sales in the quarter benefited from solid performance across all lines of the business. Chronic renal therapies, inclusive of PD, in center HD and renal therapy services, rose 3% globally. And our acute renal therapies business delivered high single-digit growth globally, driven by balanced growth in the U.S. and internationally.

    接著談我們的腎臟業務。銷售額約為11億美元,按營運口徑成長4%。本季銷售受惠於各業務線的穩健表現。慢性腎臟治療(包含PD、院內HD及腎臟治療服務)全球成長3%。而我們的急性腎臟治療業務在全球實現高個位數成長,主要由美國與國際市場均衡成長所帶動。

  • Walking through the rest of the P&L. Our adjusted gross margin of 44.3% declined 20 basis points over the prior year. Operational expansion due to positive mix, select pricing and business transformation initiatives was more than offset by the impact from lost sales due to Hurricane Maria and a negative impact from foreign exchange.

    接著說明損益表其餘項目。我們的調整後毛利率為44.3%,較去年下降20個基點。由於產品組合改善、部分定價以及業務轉型計畫帶來的營運擴張,仍不足以抵銷瑪麗亞颶風造成的銷售流失影響,以及外匯帶來的負面影響。

  • Adjusted SG&A totaled $628 million, increasing 2% on a reported basis, but declining 1% on a constant currency basis. The positive contribution from our relentless focus on effectively managing our expense base was offset by lower transition service agreement income from Shire and more than a 2-percentage-point contribution from foreign exchange.

    調整後銷售、一般及行政費用(SG&A)合計6.28億美元,按報告口徑成長2%,但按固定匯率口徑下降1%。我們持續專注於有效管理費用基礎所帶來的正面貢獻,被來自Shire的過渡服務協議收入下降,以及外匯帶來超過2個百分點的影響所抵銷。

  • Adjusted R&D spending in the quarter of $182 million increased 20% versus prior year, reflecting our stated intention to accelerate investments in our core growth businesses. Growth in the quarter also reflect the timing of some milestone payments to partners. Foreign exchange contributed 5 percentage points to growth in the quarter.

    本季調整後研發(R&D)支出為1.82億美元,較去年增加20%,反映我們先前所述將加速對核心成長業務投資的意圖。本季成長亦反映部分對合作夥伴里程碑付款的時點因素。外匯對本季成長貢獻5個百分點。

  • Adjusted operating margin in the quarter was 15.1%, a decline of 30 basis points versus the prior year. Strong operational performance in the quarter was more than offset by the loss of transition service income, foreign exchange and the impact of Hurricane Maria.

    本季調整後營業利益率為15.1%,較去年下降30個基點。本季強勁的營運表現,仍不足以抵銷過渡服務收入流失、外匯以及瑪麗亞颶風的影響。

  • Net interest expense was $14 million in the quarter. Adjusted other income totaled $24 million in the quarter primarily reflecting a benefit from foreign exchange gains on balance sheet positions. The adjusted tax rate was 17.7% for the quarter, which reflects approximately $8 million of benefit from the new stock compensation guidance. And as previously mentioned, adjusted earnings of $0.64 per diluted share exceeded our guidance of $0.56 to $0.59 per share, driven by operational strength, expense savings and a gain on foreign exchange balance sheet positions.

    本季淨利息費用為1,400萬美元。本季調整後其他收益合計2,400萬美元,主要反映資產負債表部位之外匯收益帶來的利益。本季調整後有效稅率為17.7%,其中包含新股權薪酬指引帶來約800萬美元的稅務利益。此外,如先前所提,每股稀釋後調整後盈餘0.64美元高於我們0.56至0.59美元的指引,主要由營運動能、費用節省以及外匯資產負債表部位的收益所帶動。

  • During the fourth quarter, we repurchased approximately $290 million or approximately 4.5 million shares. These repurchases were somewhat offset by option-related dilution.

    第四季期間,我們回購約2.90億美元、約450萬股股份。這些回購部分被與選擇權相關的稀釋所抵銷。

  • Now turning to full year 2017. Sales increased 4% on a reported basis, 4% at constant currency and 5% on an operational basis. On the bottom line, adjusted earnings increased 27% to $2.48 per diluted share, driven by operational strength, the ongoing benefit from our business transformation efforts and a favorable tax rate.

    接著談2017年全年。銷售額按報告口徑成長4%,按固定匯率口徑成長4%,按營運口徑成長5%。在獲利方面,每股稀釋後調整後盈餘成長27%至2.48美元,主要由營運動能、業務轉型持續帶來的效益以及較有利的稅率所驅動。

  • Moving quickly through the rest of the P&L. Our adjusted gross margin of 44.8% increased by 90 basis points over the prior year, reflecting favorable product mix, improved pricing in select areas of the portfolio and manufacturing efficiencies. Adjusted SG&A totaled approximately $2.4 billion, decreasing by 4%. And adjusted R&D spending totaled $617 million, an increase of 9% versus the prior year. Adjusted operating margin for the year was 16%, a 240-basis-point increase versus the prior year and at the high end of our expectations.

    快速說明損益表其餘項目。我們的調整後毛利率為44.8%,較去年提高90個基點,反映有利的產品組合、投資組合中部分領域的定價改善,以及製造效率提升。調整後SG&A合計約24億美元,下降4%。調整後研發支出合計6.17億美元,較去年增加9%。全年調整後營業利益率為16%,較去年提高240個基點,並達到我們預期的高端。

  • Net interest expense was $55 million and adjusted other income totaled $47 million. The full year adjusted tax rate was 18%, which included the benefit of approximately $56 million related to new stock compensation guidance. And finally, adjusted earnings of $2.48 per diluted share exceeded our guidance of $2.40 to $2.43.

    淨利息費用為5,500萬美元,調整後其他收益合計4,700萬美元。全年調整後有效稅率為18%,其中包含與新股權薪酬指引相關約5,600萬美元的利益。最後,每股稀釋後調整後盈餘2.48美元高於我們2.40至2.43美元的指引。

  • Before turning to our 2018 outlook, I will provide some commentary regarding our cash flow performance. On a full year basis, we've generated free cash flow of more than $1.2 billion, an improvement of more than $300 million versus the prior year. Growth was driven by underlying operational performance and lower CapEx, along with a continued focus on improving the company's working capital performance.

    在談到2018年展望之前,我先就我們的現金流表現提供一些說明。以全年計,我們產生超過12億美元的自由現金流,較去年改善超過3億美元。成長主要由基礎營運表現與資本支出(CapEx)下降所帶動,同時我們也持續專注於改善公司的營運資金表現。

  • Let me conclude my comments this morning by providing our guidance for the first quarter and full year 2018. As previously mentioned, we have updated our external sales reporting structure, and I will provide guidance consistent with this new format.

    最後以提供2018年第一季與全年指引作為我今天上午的結語。如先前所提,我們已更新對外銷售報告架構,我將依此新格式提供指引。

  • Globally, we expect 2018 full year sales to increase between 6% to 7% on a reported basis, with approximately 4% on both a constant currency basis and an operational basis. I would like to point out some key assumptions reflected in our full year sales outlook, which include: approximately 250 basis points of favorable foreign exchange contribution; approximately $25 million of negative sales impact from Hurricane Maria in the first quarter; approximately $145 million in Claris sales as compared to $57 million in 2017; full year U.S. cyclophosphamide sales of approximately $95 million versus $185 million in 2017.

    在全球範圍內,我們預期2018年全年銷售額按報告口徑成長6%至7%,按固定匯率口徑與營運口徑皆約成長4%。我想指出,全年銷售展望中反映的幾項關鍵假設包括:外匯帶來約250個基點的正面貢獻;第一季因瑪麗亞颶風造成約2,500萬美元的負面銷售影響;Claris銷售額約1.45億美元(相較2017年的5,700萬美元);以及美國環磷醯胺(cyclophosphamide)全年銷售額約9,500萬美元(相較2017年的1.85億美元)。

  • We have, for the most part, anniversaried the select strategic product exits we have undertaken. And while we will continue to optimize the portfolio, we will no longer be adjusting sales for these exits.

    就大多數情況而言,我們先前所進行的部分策略性產品退出已完成週期性比較(anniversary)。雖然我們仍將持續優化產品組合,但未來將不再就這些退出項目調整銷售額。

  • And finally, this guidance does not include any contribution from the 2 hemostat and sealant products from Mallinckrodt. We continue to expect this transaction to close in the first half of the year.

    最後,本指引未包含來自Mallinckrodt的兩項止血與封合產品的任何貢獻。我們仍預期該交易將於上半年完成交割。

  • In terms of our new external reporting structure, we will no longer be classifying sales by the 2 segments of Hospital Products and Renal. Sales will now be broken down into 6 global businesses. And the segments analysis we provide will be reported by our 3 regions: Americas; EMEA, Europe, Middle East and Africa; and Asia Pacific. As Clare mentioned, we have posted schedules on our website reclassifying sales into the new global business unit structure.

    就新的對外報告架構而言,我們將不再依醫院產品與腎臟兩大部門分類銷售額。銷售額將改以6個全球業務來拆分。而我們提供的部門分析將依3個區域呈現:美洲;EMEA(歐洲、中東與非洲);以及亞太地區。如Clare所提,我們已在網站上公布相關表格,將銷售額重新分類至新的全球事業單位架構。

  • Sales guidance is being provided in the new structure on a constant currency basis. Starting with renal care, which includes our peritoneal dialysis, in-center hemodialysis and renal therapy services, we expect growth of 3% to 4%.

    銷售指引將以新的架構、並以固定匯率基礎提供。先從腎臟照護開始,包含我們的腹膜透析、院內血液透析以及腎臟治療服務,我們預期成長3%至4%。

  • Our next global business, medication delivery, which includes infusion systems, large and small volume IV solutions and our reconstitution products such as Mini-Bag Plus, we expect sales in this area to grow 6% to 7%.

    我們下一個全球業務是藥物輸送,包含輸注系統、大容量與小容量靜脈注射(IV)溶液,以及我們的復溶產品(例如Mini-Bag Plus),我們預期此領域銷售成長6%至7%。

  • The Pharmaceutical business, which includes our broad generic injectables portfolio, anesthesia and critical care products and our hospital pharmacy compounding services conducted outside the U.S. Performance in this business is expected to be flat to 2017, given some sales we recognized in 2017 that are not expected to repeat in 2018, along with increased competition for select products.

    製藥業務包含我們廣泛的學名注射劑產品組合、麻醉與重症照護產品,以及在美國以外提供的醫院藥局調劑服務。由於我們在2017年認列了部分銷售、預期2018年不會重複,加上特定產品競爭加劇,該業務表現預期與2017年持平。

  • Moving to our next global business, Nutrition, which was previously part of Integrated Pharmacy Solutions, we expect sales growth of 4% to 5%. For our advanced surgery business, we expect sales to increase 3% to 4%. For the acute therapies business, we anticipate growth of 8% to 9%, similar to 2017 levels.

    接著是我們下一個全球業務:營養(Nutrition),先前屬於整合藥局解決方案(Integrated Pharmacy Solutions)的一部分,我們預期銷售成長4%至5%。至於先進外科業務,我們預期銷售增加3%至4%。至於急性治療業務,我們預期成長8%至9%,與2017年水準相近。

  • Finally, in the other business, which primarily includes our contract manufacturing services, we expect low single-digit declines as 2017 sales benefited from a customer stockpile order, and we're projecting, also, lower manufacturing revenues from Shire.

    最後,在其他業務方面(主要包含我們的委託製造服務),我們預期將出現低個位數下滑,因為2017年銷售受惠於客戶囤貨訂單;同時我們也預估來自Shire的製造營收將較低。

  • Moving down the P&L. We anticipate adjusted operating margin expansion of 80 to 100 basis points. We expect net interest expense to total between $65 million to $70 million and adjusted other income between $50 million and $60 million for 2018.

    接著往下看損益表(P&L)。我們預期調整後營業利益率將擴張80至100個基點。我們預期2018年淨利息費用合計約為6,500萬至7,000萬美元,調整後其他收入約為5,000萬至6,000萬美元。

  • For the year, we expect an average adjusted tax rate of approximately 19.5%. The tax rate reflects approximately a 1-percentage-point benefit from the new U.S. tax reform legislation and a lower benefit from stock compensation.

    就全年而言,我們預期平均調整後稅率約為19.5%。該稅率反映了美國新稅改法案帶來約1個百分點的利益,以及來自股票薪酬的利益較低。

  • For full year 2018, we anticipate a diluted average share count of approximately 550 million shares. This reflects the benefit of certain ongoing share repurchases. Based on these factors, we expect 2018 adjusted earnings, excluding special items, of $2.72 to $2.80 per diluted share.

    2018全年,我們預期稀釋後平均流通股數約為5.5億股。這反映了部分持續進行的庫藏股回購所帶來的效益。基於上述因素,我們預期2018年調整後盈餘(不含特殊項目)為每股稀釋後2.72至2.80美元。

  • Finally, for the year, we expect to generate operating cash flow of approximately $2.1 billion. We expect CapEx of approximately $700 million. And as a result, we anticipate free cash flow of approximately $1.4 billion.

    最後,就全年而言,我們預期可產生約21億美元的營運現金流。我們預期資本支出(CapEx)約為7億美元。因此,我們預期自由現金流約為14億美元。

  • Specific to the first quarter of 2018, we expect sales growth of 5% to 6% on a reported basis and 1% to 2% on a constant currency basis. Operationally, sales in the first quarter are expected to be flat to up 1%. And we expect adjusted earnings, excluding special items, of $0.60 to $0.62 per diluted share.

    針對2018年第一季,我們預期以公告基礎計算的銷售成長為5%至6%,以固定匯率基礎計算為1%至2%。就營運面而言,第一季銷售預期持平至成長1%。我們預期調整後盈餘(不含特殊項目)為每股稀釋後0.60至0.62美元。

  • With that, we can now open up the call to Q&A.

    接下來,我們可以開放進入問答(Q&A)。

  • Operator

    Operator

  • (Operator Instructions) I would like to remind participants that this call is being recorded and a digital replay will be available on the Baxter International website for 60 days at www.baxter.com. And our first question comes from Mike Weinstein of JPMorgan.

    (接線員指示) 提醒各位與會者,本次電話會議將被錄音,並將於Baxter International網站提供60天的數位重播,網址為www.baxter.com。我們的第一個問題來自JPMorgan的Mike Weinstein。

  • Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

    Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

  • Let me start with this fourth quarter. If I back out the Puerto Rico impact from the quarter, you're at $0.70, you're right at $2.80 run rate. How do I think about that as I go into your 2018 guidance? Because, obviously, your earnings power is a lot higher than just the headline numbers suggest here.

    我先從第四季談起。如果我把本季波多黎各的影響扣除,你們是0.70美元,等於正好是2.80美元的年化運行率。在你們提出2018年指引時,我該如何看待這件事?因為很明顯,你們的獲利能力遠高於這裡標題數字所呈現的。

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Mike, we -- your method is not totally incorrect, but there's a caveat to it. The cyclophosphamide is a huge reduction, close to $100 million reduction year-over-year. We expect the new entrants -- as we don't have a crystal ball, but we have our best intelligence, so we are estimating that we're going to have 1 or 2 entrants in 2018. And that is one of the reasons by which we have a significant reduction in the EPS on a run-rate basis. We're compensating that with other things such as Claris and also we had a onetime reduction in the -- like you noted, Hurricane Maria provides a positive momentum in 2018 versus '17. But the biggest difference is the $100 million in cyclophosphamide.

    Mike,我們——你的方法並非完全不正確,但有個但書。環磷醯胺(cyclophosphamide)年對年大幅下滑,減少接近1億美元。我們預期會有新的競爭者加入——我們沒有水晶球,但我們掌握到的資訊已是最佳判斷,因此我們估計2018年會有1到2個新進者。這也是我們在運行率基礎下EPS顯著下修的原因之一。我們會用其他因素來彌補,例如Claris;另外,如你所提到的,瑪麗亞颶風(Hurricane Maria)在2018年相較於2017年也帶來一次性的正向動能。但最大的差異仍是環磷醯胺的1億美元。

  • Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

    Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

  • Okay. You bought back more stock this quarter than you had been buying back. And I was wondering if you could just talk a little bit about that in the broader context of capital allocation going forward. Obviously, there's been a lot of discussion in the last several quarters about M&A and opportunity for you guys to do some bolt-on transactions. You did Claris last year. You have the Mallinckrodt deal that's pending. But you have a balance sheet that enables you to do both bolt-on M&A and buybacks. It looks like you stepped up your activity this quarter. How should we think about it for '18? And are you assuming any incremental buybacks in your guidance?

    了解。你們本季回購的股票比之前更多。我想請你們談談,在未來資本配置的大架構下,這代表什麼。顯然,過去幾季市場一直在討論併購(M&A)以及你們進行補強型交易(bolt-on transactions)的機會。你們去年做了Claris。你們還有一筆待完成的Mallinckrodt交易。但你們的資產負債表讓你們既能做補強型併購,也能做回購。看起來你們本季加大了動作。我們該如何看待2018年?你們的指引中是否假設有任何額外回購?

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Great. Thanks for the question, Mike. Overall, if you look at 2017, we purchased a company for approximately $600 million. We also repurchased approximately $600 million worth of shares. And so if you put that in the context of free cash flow of $1.2 billion. We essentially deployed all of it. Now our objective is not relative to a free cash flow number. But I can tell you that we intend to be active, both on the business development front and on the buyback front. I've talked to you in the past about how we think about buy back. We have an internal model, which calculates the value of the shares. And as we look at the share price, we look at opportunities to purchase shares relative to that, looking for a discount. Typically, the shares trade at a discount, so we are active buyers in the marketplace. We expect to continue to do this through 2018, and we also expect to continue to do a number of bolt-on transactions. Of course, and Joe will speak to this in a moment, for us, we've to be very disciplined about business development and so it's not just about doing deals, it's about doing very positive deals for our company, similar to this Mallinckrodt deal. As far as the guidance, we have embedded some incremental guidance. We've been repurchasing shares in the quarter. This current quarter, we expect about $500 million worth of buyback currently planned, although I expect the final number will be different than that, and it will be based on the mechanics that I described earlier. Joe, you want to talk about business development?

    很好。謝謝你的問題,Mike。整體來看,如果你回顧2017年,我們以約6億美元收購了一家公司。我們也回購了約6億美元的股票。若把這放在12億美元自由現金流的脈絡下,我們基本上把它全部投入運用了。當然,我們的目標並不是以某個自由現金流數字為基準。但我可以告訴你,我們打算在業務開發與回購兩方面都保持積極。我過去也跟你談過我們如何看待回購。我們有一個內部模型,用來計算股票的價值。當我們觀察股價時,會相對於該價值評估買回股票的機會,尋找折價。通常股價會以折價交易,因此我們會在市場上積極買進。我們預期2018年會持續這麼做,同時也預期會持續進行若干補強型交易。當然,Joe稍後會談到這點;對我們而言,我們必須在業務開發上非常自律,因此不只是做交易,而是要做對公司非常有利的交易,類似這筆Mallinckrodt交易。至於指引方面,我們已納入一些額外的回購假設。我們在本季一直在回購股票。就目前這一季而言,我們目前規劃約5億美元的回購,雖然我預期最終數字會與此不同,並將取決於我先前描述的機制。Joe,你要談談業務開發嗎?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Sure. So going back to the theme of capital allocation, I think Jay described pretty accurately our ability to do all of those things together. Our intention is to look at our businesses on an adjacency basis and do those incremental deals at a higher volume and velocity, meaning more of them and a little faster as we continue to refine our M&A group. Our M&A group is now complete. We have our strategy group in place. We have a pretty well-defined boundaries where we want to go. And I never take no, never considered that large acquisitions are completely off the table. They are just difficult to come by, and they are much more difficult today to get decent returns on those. But we -- as we look opportunistic in many different things, our focus on M&A and the strategy are the adjacencies. We're going to continue to do that. But we can do the 3 things that we plan -- we have planned all along. We continue to buy shares, we're going to continue to pay the dividends and increase dividends every year like we have done in the past and do these smaller deals or deals which are complementary in higher volume and velocity.

    當然。回到資本配置這個主題,我認為 Jay 相當準確地描述了我們同時做所有這些事情的能力。我們的意圖是以相鄰領域(adjacency)的角度來檢視我們的業務,並在我們持續精進併購(M&A)團隊的同時,以更高的量與速度來進行這些增量型交易,也就是做更多、而且稍微更快。我們的併購團隊現在已經建置完成。我們的策略團隊也已到位。我們對於想要前往的方向有相當明確的邊界。而且我從未說不、也從未認為大型收購完全不在考量範圍內。只是這類機會很難遇到,而且在今天要在這些交易上取得理想報酬更為困難。但我們——在許多不同事項上都會把握機會,而我們在併購與策略上的重點是相鄰領域。我們會持續這麼做。同時,我們也能做我們一直以來規劃的三件事。我們會持續回購股票、持續支付股利並像過去一樣每年提高股利,並以更高的量與速度進行這些較小的交易或具互補性的交易。

  • Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

    Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

  • Joe, last question, I'll drop here. I don't want to get through all the different businesses and the guidance for 2018 is relative to our expectations. But there weren't too many surprises. I thought that you're probably being a bit conservative in advanced surgery given the product flow there and the R&D you've been putting to work so I'd love to hear your thoughts on that. And as well, maybe the same comment on the renal side, where there's a lot going on in really all 3 or 4 different parts of that business.

    Joe,最後一個問題我在這裡問。我不想把所有不同業務都逐一過一遍,而你們對 2018 年的指引相對於我們的預期而言,但並沒有太多意外。我覺得你們在先進外科(advanced surgery)方面可能稍微保守了一點,考量到那邊的產品推出節奏以及你們投入並落地的研發(R&D),所以我很想聽聽你的看法。另外,也許腎臟(renal)業務也可以做同樣的評論,因為那個業務的 3 到 4 個不同部分其實都有很多事情在進行。

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Thank you, Mike. I have to think that we are good forecasters of our business. And this is the beginning of the year. We always have the ability to -- for the most part, to do what we say we're going to do. So when we give a number to the Street, it's something we have confidence that we can achieve. Clearly, the year always holds surprises. We had a huge one with hurricane season. But the company had enough in the bank to be able to provide for the results that we did. I would say that we have good growth in most of our businesses, and we are -- continue to do geographic expansion product launches. So the ability to kind of exceed what we have is our ability directly related to execution on the new products in second half of the year when we come in with a new pump version for SIGMA SPECTRUM or launch of our new peritoneal dialysis automated device in Japan and geographic expansion. So if we can execute on those things, everything goes right, we'll let you guys know, and we will change our outlook for the year. But at the moment, that's what we see with a significant amount of puts and takes including cyclophosphamide.

    謝謝你,Mike。我必須說,我們對自身業務的預測能力一向不錯。而且現在是一年之初。我們通常——在大多數情況下——都有能力做到我們說要做到的事。因此當我們給華爾街一個數字時,那是我們有信心可以達成的。當然,一年之中總會有意外。我們在颶風季就遇到了一個巨大的意外。但公司帳上有足夠的緩衝,得以支撐我們所交出的業績結果。我會說,我們大多數業務都有不錯的成長,而且我們——持續進行地域擴張與產品上市。因此,我們能否超越目前目標,直接取決於我們在下半年新產品的執行力:例如為 SIGMA SPECTRUM 推出新版幫浦,或在日本推出我們新的腹膜透析自動化裝置,以及地域擴張。所以如果我們能把這些事情執行到位、各方面都順利,我們會讓各位知道,並會調整我們對全年展望。但就目前而言,這就是我們所看到的情況,其中包含相當多的利多與利空因素(puts and takes),也包括 cyclophosphamide(環磷醯胺)。

  • Operator

    Operator

  • And our next question comes from Larry Keusch of Raymond James.

    下一個問題來自 Raymond James 的 Larry Keusch。

  • Lawrence Soren Keusch - MD

    Lawrence Soren Keusch - MD

  • Just wanted to quickly start off on IV solutions. I know that you made the comments that you expect to be back in -- I think, more normalized supply in the U.S. over the coming weeks. What gets you there? Is it a combination of the ability to import and Puerto Rico continuing to ramp up? And then if you could sort of segment that between large-volume IVs and Mini-Bags?

    我想先快速從靜脈輸液(IV solutions)開始。我知道你們提到,預期在接下來幾週內,美國的供應會回到——我想是——較為正常化的水準。是什麼讓你們能達到那個狀態?是進口能力加上波多黎各產能持續爬坡的組合嗎?另外,你們能否把這部分拆分說明:大容量 IV 與 Mini-Bags(小袋裝)各自的情況?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Larry, good morning. We're going to split the conversation into 2 pieces. The piece that got affected by the hurricane is a Small Volume Parenteral that we call the SVP. Those are we call Mini-Bags, Mini-Bag Plus. And prefilled bags in small amounts for nutrition amino acids, dual chamber bags and other things like that. So we have 2 different distinctive situations. Let me talk about the small parenteral bags. We are producing at a pretty good clip at our plants in Puerto Rico. We supplemented that production with volume that is coming from Ireland, our Castlebar facility, and we'll continue to make progress. And we think by the end of the first quarter, the production -- rather not production, but inventory levels will be at a place that we can put this behind us. As we speak today, the allocation that we put out is 100%. So people can buy Mini-Bags and Mini-Bags Plus today, we just changed that, at a 100% of the average purchasing volume of 6 months ago, okay? And we will get this completely normalized by the end of the first quarter, probably earlier than that, okay? So we also had contingency plans, which will put towards the end of '18, mid '19, more capacity for Mini-Bag Plus for 2 reasons. One is we have the ability to sell as much as we make, is better for the market and more profitable for Baxter. So we're shifting the mix to benefit all the stakeholders, including ourselves in terms of profitability. The second part of the conversation is the large volume parenteral. That has nothing to do with the hurricane, that has to do with increased demand and inability of some of the manufacturers in the marketplace to make the product. We obtained permanent importation licenses and product registration from Mexico. We walk away from some of the business that we had in Mexico, which can be taken over by a local competitor and is moving their volume permanently to the U.S. The second thing is, yesterday, we just got approval from importation permits for Brazil. So now the product is going to be coming into the U.S. So by the end of this next 6 months, we will have a network of global factories that cost-effectively can bring products into the U.S. in any situation even to guarantee future contracts with our current customers and potential new customers.

    Larry,早安。我們把這段討論分成兩個部分。受颶風影響的部分是我們所稱的小容量注射劑(Small Volume Parenteral,SVP)。這些就是我們所稱的 Mini-Bags、Mini-Bag Plus。以及用於營養氨基酸等的小容量預充袋、雙腔袋(dual chamber bags)和其他類似產品。所以我們面臨兩種不同且明確的情況。我先談小容量注射袋。我們在波多黎各的工廠正以相當不錯的速度生產。我們也用來自愛爾蘭 Castlebar 廠的供應量來補充這部分產出,並會持續改善。我們認為到第一季末,產量——更精確地說不是產量,而是庫存水位——將達到一個我們可以把這件事拋在腦後的程度。就今天此刻而言,我們發布的配給(allocation)是 100%。也就是說,大家今天可以購買 Mini-Bags 和 Mini-Bags Plus;我們剛把它調整為:以 6 個月前平均採購量的 100% 供應,好嗎?而我們會在第一季末前讓它完全正常化,可能還會更早,好嗎?此外,我們也有應變計畫,將在 2018 年底、2019 年中左右,基於兩個原因,為 Mini-Bag Plus 增加更多產能。第一,我們有能力把做出來的量都賣掉,這對市場更好,對 Baxter 的獲利也更好。因此我們正在調整產品組合,以讓所有利害關係人受益,包括我們自己在獲利方面。第二部分是大容量注射液(large volume parenteral)。那與颶風無關,而是因需求增加,以及市場上一些製造商無法生產該產品所致。我們已取得來自墨西哥的永久進口許可與產品註冊。我們會退出在墨西哥的一部分業務,這部分可由當地競爭者承接,並將其產能永久轉移到美國。第二件事是,我們昨天剛取得來自巴西的進口許可核准。因此產品現在將會進入美國。接下來 6 個月結束時,我們將擁有一個全球工廠網絡,能以具成本效益的方式在任何情況下把產品運到美國,甚至能確保與現有客戶及潛在新客戶的未來合約供應。

  • Lawrence Soren Keusch - MD

    Lawrence Soren Keusch - MD

  • Okay, that's terrific and very helpful. And then one other one maybe a little bit longer in nature. I think, Joe, that you've been focused on Japan as an opportunity. It sounds like you guys are fairly underindexed there relative to other large multinational U.S. companies. So just briefly, how do we think about the opportunity there in Japan? And what are you doing?

    好的,那太棒了,而且非常有幫助。接著還有一個問題,可能性質上會稍微長一點。我想,Joe,你一直把日本視為一個機會。聽起來相較於其他大型美國跨國公司,你們在那裡的布局比重相對偏低。所以簡單說一下,我們該如何看待日本的機會?你們正在做些什麼?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Japan, the first opportunity for us is to capitalize in a tremendously underpenetrated peritoneal dialysis business. Japan has a very, very, very rich reimbursement for PD, and we make significant amount of profit from that modality. But the volume compared to the rest of the world is quite small. So by launching the new Kaguya cycler in Japan, we'll be able to satisfy some of the market needs, for instance, it's more the connectivity of the tubing in this machine is done automatically hands-free. So there's some peculiarities that Japan requires to adopt technologies different. We, as a company, have done not a great job in Japan once we separate from Baxalta because Baxalta was a bulk of the business in Japan. And our business now will focus on augmentation of the PD, launching new advanced surgery products in Japan as well as augmenting the pharmaceutical capabilities in Japan. So this is a more of a long-term road map, but I tell you, that is one that has our focus. Andy Frye now is the President for Asia. Japan falls under him, and we have significant plans for talent improvement to be able to get those things there.

    日本方面,我們的第一個機會是把握腹膜透析(PD)這個滲透率極低、但潛力巨大的業務。日本對PD的給付非常、非常、非常優渥,而我們在這種治療模式上能取得相當可觀的利潤。但相較於世界其他地區,日本的量其實相當小。因此,透過在日本推出新的 Kaguya 自動腹膜透析機(cycler),我們將能滿足部分市場需求;例如,這台機器的管路連接更具連線性,且可自動、免手動操作(hands-free)完成。所以日本在採用技術上有一些特殊要求,需要不同的導入方式。我們公司在與 Baxalta 分拆之後,在日本做得並不算好,因為 Baxalta 過去在日本占了大部分業務。而我們現在的業務將聚焦於擴大PD、在日本推出新的先進外科產品,以及強化在日本的製藥能力。這比較像是一個長期路線圖,但我可以告訴你,這是我們的重點之一。Andy Frye 現在是亞洲區總裁。日本隸屬於他之下,我們也有相當多的人才提升計畫,以便能把這些事情在當地落地推進。

  • Operator

    Operator

  • And our next question comes from Vijay Kumar of Evercore ISI.

    下一個問題來自 Evercore ISI 的 Vijay Kumar。

  • Vijay Muniyappa Kumar - MD & Fundamental Research Analyst

    Vijay Muniyappa Kumar - MD & Fundamental Research Analyst

  • So maybe, Jay, on the Q1 guidance -- on the revenue guidance. So some of the questions I'm getting is, if sequentially, you had capacity coming back from Puerto Rico, right? Was this guide a little bit tad below? Or what was the Street mismodeling on some of the line items?

    那也許,Jay,關於第一季(Q1)指引——關於營收指引。我收到的一些問題是,如果按季來看,你們的產能正從波多黎各回來,對吧?那這次的指引是不是稍微偏低了一點?或者說,市場(Street)在某些科目上是哪裡建模錯了?

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Yes, just a couple of things to point out in relation to Q1 sales growth, which, to your point, Vijay, is below the run rate we expect for the balance of the year. Solid operational performance, but Puerto Rico does impact us by 1 point of growth. And then the other comment I would make is, last year, we had a bolus of sales related to a product called Transderm Scop. And year-over-year, that's about a 1% headwind. So those 2 items collectively dragged down the growth a little bit below what we expect moving forward. The other thing that happens as we approach the latter part of the year is we start to benefit from some of the new product launches. Joe mentioned Kaguya. We are also extremely excited about the Version 9 Spectrum pump, which we anticipate launching towards the first -- end of the first half of the year. So that starts to benefit and accelerate some growth. So 2 very specific items and then certain benefit from new products is really the story on Q1 relative to rest of the year sales guidance.

    是的,關於第一季銷售成長,有幾點需要說明;正如你所說,Vijay,這低於我們預期全年其餘期間的運行水準(run rate)。營運表現穩健,但波多黎各確實對我們造成約 1 個百分點的成長影響。另外我想補充的是,去年我們有一筆與一個名為 Transderm Scop 的產品相關的銷售脈衝(bolus)。以年對年來看,這大約帶來 1% 的逆風。因此這兩項合計,讓成長率比我們對未來的預期略低一些。另外,當我們接近下半年時,會開始受惠於一些新產品上市。Joe 提到了 Kaguya。我們也對 Spectrum 幫浦第 9 版非常興奮,預計在上半年末、接近上半年結束時推出。因此這會開始帶來助益並加速部分成長。所以,第一季相較於全年其餘期間的銷售指引,重點就是兩個非常具體的因素,再加上新產品帶來的某些助益。

  • Vijay Muniyappa Kumar - MD & Fundamental Research Analyst

    Vijay Muniyappa Kumar - MD & Fundamental Research Analyst

  • That's helpful. Jay, just a couple of quick guidance follow-ups. One on the segment details. This is extremely helpful, the historical numbers you gave out. But on medication delivery, right, so if capacity is coming back from Mexico repurposing capacity, right? So if I'm looking at that year-on-year, it looks like flattish to maybe up slightly. So one, are we fair to assume this guidance of 6% to 7% from med delivery does not assume incremental share gains? And I have one follow up on the free cash.

    這很有幫助。Jay,再追問幾個很快的指引問題。一個是關於分部細節。你提供的歷史數字非常有幫助。但在藥物輸注/給藥(medication delivery)方面,對吧,如果產能正從墨西哥回來、把產能重新調配(repurposing capacity),對吧?所以如果我看年對年,似乎是持平到小幅成長。所以第一,我們是否可以合理假設,藥物給藥 6% 到 7% 的指引並未假設額外的市占提升?另外我還有一個關於自由現金的追問。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Yes. As we look at 2018 performance for medication delivery, we are going to benefit certainly from the reallocation of sales back to the U.S. from IVs from some of the markets that Joe mentioned early on. So that certainly is a tailwind for us. What I will tell you is, over the last several years, we benefited from a number of items, including the relaunch of Version 8 pump, which featured prominently in our numbers for a number of quarters. We also benefited from renegotiation of select agreements that we had in place with GPOs. So there is -- we've always anticipated and we've modeled long term that there would be a deceleration in the growth, in particular, in the U.S. over time. But this is -- this guidance is largely consistent with our expectations and does reflects some benefit of the reallocation of products.

    是的。我們看 2018 年藥物給藥業務的表現,確實會受惠於把部分市場的靜脈輸液(IV)銷售重新分配回美國——這點 Joe 先前有提到。所以這對我們確實是順風。我想說的是,過去幾年我們也受惠於多項因素,包括第 8 版幫浦的重新上市(relaunch),在好幾個季度的數字中都占了很重要的比重。我們也受惠於與部分 GPO(集團採購組織)重新談判既有協議。因此——我們一直預期、也在長期模型中納入:成長會放緩,特別是美國市場的成長會隨時間而減速。但這份指引大致符合我們的預期,且確實反映了產品重新分配所帶來的一些助益。

  • Vijay Muniyappa Kumar - MD & Fundamental Research Analyst

    Vijay Muniyappa Kumar - MD & Fundamental Research Analyst

  • Just one on free cash, Jay, and apologies for the extra question. The free cash guidance so that's a -- call it, double-digit growth for '17. But if we're looking at the 2020 targets of $2 billion, so that assumes free cash accelerates back to high teens. Was there any timing impact for '18 when you look at the free cash number?

    再問一個關於自由現金的問題,Jay,也抱歉多問一題。自由現金指引——如果這麼說,較 2017 年是雙位數成長。但如果我們看 2020 年 20 億美元的目標,那就意味著自由現金成長會再加速回到高十幾%的水準。從 2018 年的自由現金數字來看,是否有任何時點(timing)因素的影響?

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • What I will tell you is, relative to the guidance that we shared in July, our confidence in our long-term ability to generate cash flow has increased in the sense that we had a great 2017 performance ahead of our expectations, so solid performance on free cash flow. Not really timing items specifically, I think we were pleased to exceed $1.2 billion. $1.4 billion will reflect continued performance with respect to working capital management, which we are driving relentlessly, along with continued operating income growth. So stay tuned. We'll watch this one closely. It's always very difficult at the start of the year to predict cash flow. It's a highly volatile number. It's the most -- frankly, it's the most challenging one for us to predict on a full year basis. So stay tuned. We'll watch this one carefully as we go on. But I will tell you, the performance of our team on the supply chain side, on the accounts payable, receivable side, very good performance, and we're tracking where we want to be on the free cash flow side.

    我可以告訴你的是,相較於我們在 7 月分享的指引,我們對長期產生現金流的能力更有信心;原因在於 2017 年的表現優於我們的預期,自由現金流表現穩健。並沒有特別的時點因素;我想我們很高興能超過 12 億美元。14 億美元將反映我們在營運資金管理上的持續表現——我們正不懈地推動——同時也包括持續的營業利益成長。所以請持續關注。我們會密切觀察這一項。每年年初要預測現金流總是非常困難。這是一個波動性很高的數字。坦白說,這是我們在全年基礎上最具挑戰、最難預測的一項。所以請持續關注。我們會在推進過程中仔細追蹤。但我可以告訴你,我們團隊在供應鏈端、以及應付帳款與應收帳款端的表現都非常好,我們在自由現金流方面的進度也符合我們希望達到的方向。

  • Operator

    Operator

  • And our next question comes from Matt Taylor of Barclays.

    我們的下一個問題來自巴克萊(Barclays)的 Matt Taylor。

  • Matthew Charles Taylor - Director

    Matthew Charles Taylor - Director

  • The first question I wanted to ask was just around the injectables outlook and Claris. I guess, you gave us a number for Claris. I was hoping maybe you could supplement that with some color on what you're expecting from your internal program? And maybe any update on the Claris 483 unit and how you're doing with remediation there?

    我想問的第一個問題是關於注射劑的展望以及 Claris。我想,你們已經給了我們一個 Claris 的數字。我希望你們或許可以再補充一些你們對內部專案預期的細節與說明?另外,Claris 的 483 單(觀察事項)有沒有任何最新進展,以及你們在那邊的改善(remediation)進度如何?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • We are -- continue to pursue the internal development. We are launching a coronary drug, just got approved. We have other drugs planned to be launched here, either frozen or non-frozen, they're made by GALAXY. We continue to launch products outside Claris -- outside the U.S. for Claris. And the 483 is quite simply, we have done to date everything that we said we were going to do. We're still not finished. We have a couple more things to do, but we're still in the timeline and some of the things we're doing we're ahead of time of our time line. We are optimistic of what we're doing is going to resolve the issue outlined in the 483, but we are not the agency, so we cannot speak on behalf of the agency. We do everything we can to satisfy what we said to the agency we are going to do, and we feel comfortable that we are doing that. Now versus with the FDA to make that determination, but we are working very hard and we have integrated significant amount of quality systems into the Baxter quality systems. And if you went to the facility today, you would see a very significant amount of physical improvement in things that we've done to correct issues that we personally, as a company, have found and some that the FDA has found on top of our findings.

    我們會——持續推進內部開發。我們正在推出一款冠狀動脈用藥,剛剛獲得核准。我們也規劃在這裡推出其他藥品,可能是冷凍或非冷凍,這些由 GALAXY 製造。我們也持續在 Claris 之外——也就是在美國以外——推出 Claris 的產品。至於 483,很簡單:截至目前,我們已經完成了我們說過要做的所有事情。我們還沒有全部完成。我們還有幾件事要做,但我們仍在既定時程內,而且有些工作甚至比時程更提前。我們對於我們正在做的事情能夠解決 483 中列出的問題感到樂觀,但我們不是主管機關,因此無法代表主管機關發言。我們會盡一切所能去滿足我們向主管機關承諾要做的事項,我們也有信心我們正在做到這一點。接下來就由 FDA 來做出判定,但我們正非常努力,也已將大量品質系統整合進 Baxter 的品質系統中。如果你今天去那個廠區,你會看到我們為了修正問題所做的非常顯著的實體改善——包括我們公司自己發現的問題,以及 FDA 在我們發現之外另外指出的一些問題。

  • Matthew Charles Taylor - Director

    Matthew Charles Taylor - Director

  • And I want to give you a chance to -- without biasing you, maybe talk about some of the tailwinds from a product standpoint in 2018 and specifically, would like to hear from you products that you think could make a difference that you believe are underappreciated by investors?

    我想給你一個機會——在不引導你答案的前提下——談談 2018 年從產品角度來看有哪些順風因素(tailwinds)。

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • I'll focus on 3 or 4 areas. First of all, I think our ability to provide the market with LVPs and SVPs add the volumes that the market not only needs, but potentially has competitive -- going to competitive accounts is a potential upside. We don't know if that's going to materialize the competitive accounts, but we know that we now have solid factories being completely focused in the U.S. market. Baxter is the largest manufacturer of solutions in the world and having not used that capability in the past was a mistake. Now we are fully engaged in using this capability and flexibility across the globe. So that is a positive. I think the new pump -- the new version of our pump, SIGMA SPECTRUM, coming out now second half of the year is a good thing. The pump has really new features and new things that we think are needed in the marketplace and people waiting for it. So our ability to launch that well offers the possibility to be a positive for us. The third one is the launch of the Kaguya in Japan. I think that is a positive. And geographic expansion, lastly is, we're starting to get products approved. We just got one approved in China the other day. Actually, early this week. We just got a monitor, AK 98, approved in China for sale, way ahead of time. So our people are starting to work very diligently on new products to be able to get those things to augment our objective in the midterm, which is to get the company to a 5% top line growth.

    我會聚焦在 3 到 4 個領域。首先,我認為我們向市場提供 LVP 與 SVP 的能力,能夠增加市場不僅需要、而且可能具競爭性的供應量——去爭取競爭對手的客戶(competitive accounts)是一個潛在上行空間。我們不確定競爭對手客戶是否會轉化,但我們知道我們現在有穩健的工廠,並且完全聚焦於美國市場。Baxter 是全球最大的輸液解決方案製造商,而過去沒有運用這項能力是一個錯誤。現在我們已全面投入,運用這項能力以及全球範圍內的彈性。所以這是一個正面因素。我認為新幫浦——我們幫浦的新版本 SIGMA SPECTRUM——將在今年下半年推出,這是件好事。這款幫浦有真正的新功能與新特性,我們認為市場需要,而且大家也在等待它。因此,我們若能順利推出,可能會對我們帶來正面影響。第三個是 Kaguya 在日本的上市。我認為那是正面因素。最後是地理擴張:我們開始讓產品取得核准。我們前幾天剛在中國拿到一項核准。其實就在本週稍早。我們剛讓一款監測器 AK 98 在中國獲准銷售,而且比預期時程早很多。因此,我們的團隊正非常努力推進新產品,讓這些成果能夠強化我們中期目標,也就是讓公司營收(top line)成長達到 5%。

  • Operator

    Operator

  • And our next question comes from Danielle Antalffy of Leerink Partners.

    我們的下一個問題來自 Leerink Partners 的 Danielle Antalffy。

  • Danielle Joy Antalffy - MD, Medical Supplies and Devices

    Danielle Joy Antalffy - MD, Medical Supplies and Devices

  • Just to follow up, if I could, Jay. And I know you guys will provide more detail on this at the upcoming Analyst Day, so not trying to front run too much. But just at a high level, if you think about beyond 2018, and what in the pipeline -- and, Joe, maybe this is a question for you as well, what do you see is the key pipeline initiatives that are going to drive accelerating growth beyond the 4% operationally you're projecting in 2018? Number one. And then Jay, for you, number two, the incremental leverage you can pull on the P&L to drive positive leverage in the out years considering feels like a lot of low-hanging fruit might have already been picked here?

    Jay,如果可以的話,我想追問一下。我知道你們會在即將到來的分析師日提供更多細節,所以我不想太早搶先問太多。但就高層次來看,如果你們思考 2018 年之後,以及產品管線(pipeline)方面——Joe,或許這題也想請你回答——你們認為哪些關鍵的管線計畫,將推動 2018 年你們所預測的 4% 營運成長(operationally)在 2018 年之後進一步加速?這是第一點。第二點,Jay,想請教你:在未來幾年,考量到感覺很多「低垂的果實」可能已經被摘取,你們還能在損益表(P&L)上拉動哪些額外槓桿,以在未來年度帶來正向的營運槓桿(positive leverage)?

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Yes, Danielle, I'll start by talking about the operating margin levers that we have and then, Joe, perhaps you can talk about some of the exciting pipeline products that start to accelerate growth as we move past 2018. And by the way, it's a bit premature to talk about '19 and '20 as we sit here on February 1 so at the risk of doing that. I think we are very pleased with the transformation efforts on the cost side. Danielle, your question is a good one because, to a large extent, we have taken a lot of low-hanging fruit and reflected that in our numbers over the last couple of years in terms of implementing zero-based budgeting, and certain other tactics that we've employed. As we look to 2019, '20 and beyond, there are certain more complicated or a bit more challenging programs that we have on the back office with respect to G&A. And perhaps it's better to say longer lead time items as we look to transform our back office to streamline shared service centers. We've made tremendous progress, our functions have done really amazing work. But our expectation all along is that those would not have an impact in 2016 or '17, but would start to play out as we are seeing in 2018 and then '19 and '20. So that's one area I would say. And then the other thing that's going to be very interesting as we move to 2019 and '20 is our manufacturing team has done a great job in terms of controlling costs. Now, obviously, that team has been very focused on responding to things like natural disasters and tight supply situation. So they've been very focused on that. But at the same time, they've been very focused on optimizing our manufacturing network and optimizing operations within our manufacturing network. And so moving to 2019 and '20, we continue to expect very solid performance coming out of that team, along with a restored supply situation. Now with respect to acceleration of growth on the top line and products that are going to drive that, Joe, maybe you could take that one.

    好的,Danielle,我先談談我們可運用的營業利益率(operating margin)槓桿,然後 Joe 也許可以談談一些令人振奮、在我們走過 2018 年後開始加速成長的管線產品。順帶一提,在 2 月 1 日的此刻談 '19 與 '20 其實有點太早,但在這個前提下我還是試著回答。我們對於成本端的轉型努力感到非常滿意。Danielle,你的問題問得很好,因為在很大程度上,我們已經摘取了不少「低垂的果實」,並在過去幾年把這些反映在數字上,例如推行零基預算(zero-based budgeting)以及我們採取的其他一些策略。展望 2019、'20 及之後,在後勤(back office)與一般及行政費用(G&A)方面,我們有一些更複雜或更具挑戰性的計畫。或許更好的說法是,當我們要轉型後勤、精簡共享服務中心(shared service centers)時,這些是需要較長前置時間的項目。我們已取得巨大進展,各職能團隊做了非常出色的工作。但我們一開始的預期就是,這些不會在 2016 或 '17 產生影響,而是會如我們在 2018 所看到的那樣開始展現,並延續到 '19 與 '20。所以這是一個面向。另外,當我們走向 2019 與 '20 時,另一個很有意思的點是,我們的製造團隊在成本控管方面做得非常好。當然,那個團隊一直非常專注於因應像是天然災害與供應吃緊等情況。所以他們在那方面投入很多。但同時,他們也非常專注於最佳化我們的製造網路,以及在製造網路內最佳化營運。因此,進入 2019 與 '20,我們仍預期該團隊會有非常穩健的表現,同時供應狀況也將恢復。至於營收端(top line)的加速成長,以及將推動成長的產品,Joe,也許你可以回答這一題。

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Sure. Our midterm goal for the top line is 5%, okay? We're working very hard to get there. And to get there is the ability to launch those new products a little better than we have planned. And there is opportunities for that. So the first one, as I said, is optimization of the supply chain and having the right product in the right place in the U.S. I feel confident on that. The second is to launch the product in Japan, the Kaguya, the cycler in Japan. The third is geographic expansion, get this thing right. Fourth, the pump, the SIGMA SPECTRUM is half a deal. Remember, our medication delivery guidance for global growth is between 6% and 7% for 2018, which is pretty good growth, okay? Then let's look at a little bit more on the midterm. Let's talk about '19 and beyond. THERANOVA. THERANOVA is a game-changer in in-center HD. So having that thing, having the product completely approved in the U.S., have the clinical trials in and have the ability to drive adoption in the U.S. is key for us to continue to grow. Launching PrisMAX, which is our new acute renal care CRRT monitor in the U.S. will drive continuously more growth in the U.S. We are already market leaders in acute renal care with the CRRT modality. This is over $1 billion in market. We only have this modality, which is CRRT, Continuous Renal Replacement Therapy, has only 50% or less of the overall market. So the conversion is great. Also getting in other modalities in the acute renal care is a desire of ours. And please don't forget that some of these acquisitions that we're making will have organic impact in the company once they anniversary, meaning they have their own growth. We're not buying businesses that have 0% growth. So we're buying business, they have the ability like Claris, because 12%, 14% growth happen in 2018. So there is opportunity going forward. We're seeding the way to be able to get to 5%. And like Jay said, with a significant smaller cost base for the company to operate brings a very desirable formula to the table.

    當然。我們中期在營收端(top line)的目標是 5%,好嗎?我們正非常努力要達成。而要達成,關鍵在於把那些新產品的上市推進做得比我們原先規劃得更好一些。而且這方面確實有機會。所以第一個,如我所說,是供應鏈最佳化,並在美國把對的產品放在對的地方。我對此很有信心。第二個是在日本推出產品,也就是 Kaguya,在日本推出 cycler。第三個是地理擴張,把這件事做對。第四個是幫浦,SIGMA SPECTRUM 只完成了一半的交易。請記得,我們對藥物輸送(medication delivery)2018 年全球成長的指引是 6% 到 7%,這是相當不錯的成長,好嗎?接著我們再多看一點中期。我們談談 2019 年及以後。THERANOVA。THERANOVA 對院內血液透析(in-center HD)是顛覆性的產品。因此,讓這個產品在美國完全獲批、完成臨床試驗,並具備在美國推動採用(adoption)的能力,對我們持續成長至關重要。在美國推出 PrisMAX(我們新的急性腎臟照護 CRRT 監測設備)將持續帶動美國更多成長。我們在急性腎臟照護的 CRRT 治療模式上已是市場領導者。這是一個超過 10 億美元的市場。我們目前只有這個治療模式,也就是 CRRT(Continuous Renal Replacement Therapy,連續性腎臟替代治療),而它在整體市場中的占比只有 50% 或更低。所以轉換空間很大。此外,切入急性腎臟照護的其他治療模式也是我們的目標。也請別忘了,我們正在進行的一些併購,在滿一年(anniversary)後會對公司產生有機影響,意思是它們本身就有成長。我們不是在買成長率為 0% 的業務。所以我們買的是有能力的業務,例如 Claris,因為 2018 年可以達到 12%、14% 的成長。因此未來仍有機會。我們正在鋪路,以便能達到 5%。而且如 Jay 所說,公司以顯著更小的成本基礎來運作,會帶來一個非常理想的組合。

  • Operator

    Operator

  • And your next question comes from David Lewis of Morgan Stanley.

    下一個問題來自摩根士丹利(Morgan Stanley)的 David Lewis。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • Just a couple of questions, Jay, and maybe one for Joe. Jay, just thinking about the pacing of 2018 numbers, thanks for the description of first quarter top line. Just on the bottom line, Jay, I think our math has 50 bps of margin maybe for the first quarter. Can you just talk about the factors impacting the bottom line for the first quarter? And then as you think about the third quarter, that's the other tough comp this year, should we also expect growth to be a little low in the third kind of similar to the first?

    我有幾個問題,Jay,可能也有一個要問 Joe。Jay,談到 2018 年數字的節奏,謝謝你對第一季營收端的說明。就獲利端(bottom line)而言,Jay,我想我們的推算是第一季毛利率大概有 50 個基點(bps)。你能談談影響第一季獲利端的因素嗎?另外,當你看第三季時,那是今年另一個比較難的比較基期(tough comp),我們是否也應該預期第三季的成長會有點偏低,類似第一季?

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Yes. I think that in the first quarter, to your point, we're seeing the lowest level of sales growth of the year. And then also as we look at the bottom line, there are a number of factors in play that impact bottom line growth. The first one being Puerto Rico, that's a couple of cents of margin impact that we expect to see, and that's probably the most prominent. On the operating margin line, the Puerto Rico impact is roughly 40 basis points. Some of the others -- the TDS sales item, that does not really have a bottom line impact. So I would say that if you adjust for that, along with a tough TSA comp, which represents about a 50-basis-point impact in the first quarter, remember, we -- that ceases to be an issue for us in the second half of the year. Those 2 items really explain why the margin would be the lowest growth rate in the first quarter relative to the other quarters in the year, and we start to see acceleration there. So really, those are the 2 items explaining about roughly 1 point of the growth. As we look to the balance of the year, we do expect to see solid performance throughout. And so 2018, the third quarter does represent the tough sales comp. But importantly, we'll start to benefit from some of the new product launches, so the Version 9 of the Spectrum pump just starts to feature in our Q3 results. So I think that on balance, we feel quite good about the quarterly forecast. Q1, a little bit of a slower start, but again, that is entirely explained by things like Puerto Rico and TDS. And then as we move through the rest of the year, the story becomes consistent with the full year picture. The one item I would say in Q3, we do have a $20 million compounding settlement in our 2017 results, so we'll probably talk about that. But beyond that, I think it's fairly steady progress.

    是的。我認為第一季,如你所說,我們看到的是全年最低的銷售成長水準。同時在獲利端方面,有多個因素在發揮作用,影響獲利成長。第一個是波多黎各,這會對利潤率造成約幾美分的影響,我們預期會看到,而這可能是最主要的因素。在營業利益率(operating margin)這一行,波多黎各的影響約為 40 個基點。其他一些因素——TDS 的銷售項目,基本上不會對獲利端造成影響。所以我會說,如果你把那個調整掉,再加上一個艱難的 TSA 比較基期(tough TSA comp),它在第一季約代表 50 個基點的影響;請記得,我們——這在下半年就不再是我們的問題。這兩個項目確實解釋了為什麼第一季的利潤率成長會是全年各季中最低的,相較於其他季度,之後我們會開始看到加速。所以基本上,這兩個項目解釋了大約 1 個百分點的成長差異。展望今年其餘時間,我們確實預期整體表現會很穩健。因此在 2018 年,第三季確實是銷售比較基期較艱難的一季。但重要的是,我們將開始受惠於一些新產品上市,因此 Spectrum 幫浦的第 9 版會開始反映在我們第三季的結果中。所以整體而言,我們對季度預測感覺相當不錯。第一季起步稍慢,但同樣地,這完全可以用波多黎各與 TDS 之類的因素來解釋。接著隨著我們走過今年其餘時間,故事就會與全年全貌一致。我在第三季要補充的一點是,我們在 2017 年的結果中有一筆 2,000 萬美元的配製(compounding)和解金,因此我們可能會談到這個。但除此之外,我認為進展會相當平穩。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • Jay, very clear. And Joe, just kind of 2 strategic questions for you. I guess, the first is, (inaudible) is this breaking out of these global business structures, it occurs to me that some of the businesses you're breaking out actually have dramatically faster end market growth rates. I mean, as you think about this new structure, are you starting to be of the view that the weighted average market growth rate for this business is frankly, closer to 5% relative to 4%?

    Jay,很清楚。Joe,我有兩個策略性問題想請教你。我想第一個是,(聽不清)關於把這些全球業務架構拆分出來,我注意到你們拆分出來的一些業務,其終端市場成長率其實快得多。也就是說,當你看這個新架構時,你是否開始認為這項業務的加權平均市場成長率,坦白說更接近 5% 而不是 4%?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • I think, David, our weighted average market growth rate for the overall business is 3%, okay? But the ability to perform at 5% has to do with new product launches and the ability to focus, so hence, the organizational restructuring. We were not focused and not deploying capital some time ago to the right business despite the fact our intention was that. But the organization structure was not repaired. What is allowed us to do is twofold: get people paid on global growth for certain franchise; second, allow us to really put people in those business with more specialization, given Exemplar Pharmaceuticals, for instance. We have a big mount to climb with $100 million in headwind on cyclophosphamide. Now having execution on Claris and our own organic molecules is key. To do that, you've got to have people who understand the generic pharmaceutical businesses. This is not a hospital product. This is not the same people who will do design infusion lines and infusion pumps, it's completely different. So we brought and are bringing people who have the ability to bring this business to the next level. So this reflects more how we want to pay people, how we want people to focus and also to get to our 5% objective on the top line.

    David,我認為我們整體業務的加權平均市場成長率是 3%,好嗎?但能夠做到 5% 的表現,取決於新產品上市以及聚焦的能力,因此才會有組織重整。一段時間以前,我們並沒有聚焦,也沒有把資本配置到正確的業務上,儘管我們的意圖是如此。但組織架構沒有被修復。這讓我們能做的有兩件事:第一,讓某些事業群的人員薪酬與全球成長掛鉤;第二,讓我們能把更具專業化的人才真正放到那些業務中,例如 Exemplar Pharmaceuticals。我們在 cyclophosphamide 上有 1 億美元的不利因素(headwind)要克服,這是一座很大的山要爬。現在,對 Claris 以及我們自有的有機分子(organic molecules)的執行力是關鍵。要做到這點,你必須有了解學名藥(generic pharmaceutical)業務的人。這不是醫院產品。這也不是同一批會去設計輸液管路與輸液幫浦的人,完全不同。因此我們引進並正在引進具備能力、能把這項業務帶到下一個層級的人才。所以這更反映了我們希望如何付薪、希望大家如何聚焦,以及如何達成我們營收端 5% 的目標。

  • Operator

    Operator

  • And our next question comes from Larry Biegelsen of Wells Fargo.

    我們的下一個問題來自富國銀行(Wells Fargo)的 Larry Biegelsen。

  • Lawrence H. Biegelsen - Senior Analyst

    Lawrence H. Biegelsen - Senior Analyst

  • So I wanted to start with the operating margin guidance and the goal for 2020. I think of 28%, Jay. So this year, I think, you're guiding to 80 to 100 basis points of operating margin improvement. I guess, that implies that you'd need about 150 per year in '19 and '20 to reach the 28%. So why only 80 to 100 this year in that acceleration? I think earlier, in prior calls, I think there was an impression that you could do a little better than 28%. Do you still feel that you can exceed that number? And I had one follow up.

    我想先從營業利益率指引以及 2020 年的目標談起。我記得是 28%,Jay。所以今年我想你們指引的是營業利益率改善 80 到 100 個基點。我猜這意味著你們在 2019 和 2020 年每年大約需要 150 個基點,才能達到 28%。那為什麼今年在加速上只有 80 到 100 個基點?我想之前在過去的電話會議中,大家的印象是你們可以做得比 28% 更好一些。你們仍然覺得可以超過那個數字嗎?我還有一個追問。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Yes, great. I'll talk about 2018. As far as 2020, we remain very confident in our ability to drive the business going forward. So I would insert a brief commercial for our May Investor Day, we look forward to updating our long-term financial projections for both 2020 and beyond, which the whole team is really excited about that. As it relates to 2018 guidance, there's actually 3 items that I think are worthwhile pointing out that provide some color because on the one hand, you could say, hey, it's 80 to 100 basis points, and that's what we expect, but there's 3 headwinds to point out. First, cyclophosphamide is approximately 70 basis points of impact in this year. So that's an assumption that we've made. We'll see. We'll monitor this very closely, but that's a very big drag on 2018 and frankly, as we look at margin performance over the next 3 years, we're modeling the largest single impact occurring in 2018. The second item is we have approximately 40 basis points of impact from TSA income loss. So again, that's an item that is explicit to 2018 that does not impact future years. The final thing I would comment on is we have adopted the new guidance for pension accounting. And what that means is a number of items have moved below the line, and there's certain items maintained above the line, and this will be spelled out in detail in our 10-K. But at the highest level, reflecting this guidance, it's about a 40-basis-point drag on our results in 2018. We'll footnote this and describe in a lot of detail like I say in our 10-K. There will also be some additional information available related to 2017 impact. But simply put, in our 80 to 100 basis points, there's 40 basis points of headwinds related to the new pension accounting. So as we think about what those drivers add up to, that's about 150 basis points of drag that we worked through this year on our way to achieving the 80 to 100 basis points of margin improvement. We don't expect similar magnitude, and so it becomes, we can be -- we can sit here confidently and say we feel very solid about 2019 and '20 performance.

    好的,很棒。我先談 2018 年。至於 2020 年,我們對於推動未來業務的能力仍然非常有信心。所以我想先簡短插播一下我們 5 月的投資人日,我們期待更新我們對 2020 年以及更長期的財務預測,整個團隊對此都非常興奮。就 2018 年指引而言,我認為有 3 個值得指出、能提供一些背景的項目;因為一方面你可以說,嘿,就是 80 到 100 個基點,這是我們的預期,但同時也有 3 個逆風需要說明。第一,cyclophosphamide(環磷醯胺)今年大約影響 70 個基點。這是我們所做的假設。我們會再看看。我們會非常密切地監控,但這對 2018 年是很大的拖累;坦白說,當我們看未來 3 年的利潤率表現時,我們模型中最大的單一影響發生在 2018 年。第二項是,我們因 TSA 收入流失大約有 40 個基點的影響。同樣地,這是 2018 年特有的項目,不會影響未來年度。最後我想評論的是,我們已採用新的退休金會計指引。這代表有一些項目被移到損益表的線下(below the line),也有某些項目仍維持在線上(above the line),我們會在 10-K 中詳細說明。但就最高層級來看,反映這項指引後,對我們 2018 年的結果約有 40 個基點的拖累。如我所說,我們會在 10-K 的註解中非常詳細地說明。也會提供一些與 2017 年影響相關的額外資訊。但簡單來說,在我們的 80 到 100 個基點之中,有 40 個基點的逆風與新的退休金會計相關。因此當我們思考這些驅動因素加總起來,今年我們在達成 80 到 100 個基點利潤率改善的過程中,實際上克服了約 150 個基點的拖累。我們不預期會再出現同等幅度的影響,因此我們可以——我們可以很有信心地坐在這裡說,我們對 2019 年與 2020 年的表現感到非常踏實。

  • Lawrence H. Biegelsen - Senior Analyst

    Lawrence H. Biegelsen - Senior Analyst

  • That's very helpful. Just lastly for me. Joe, any update on emerging market performance?

    這非常有幫助。最後一個問題。Joe,新興市場表現有任何更新嗎?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Yes. We had pretty good performance in emerging markets. We got about 6.7%, close to 7% in emerging markets for the year. We also had China over 6%, which is great for us. I just want to underscore that emerging markets like medical devices qualify does not apply to Baxter. We've been in those markets for a long time. So China, for us, is a good growth market, has good GDP growth, and that represents an opportunity for us to geographically expand new product lines there as well as Brazil and Mexico, Colombia, I see those as probably the most prominent and then Southeast Asia. So we do emerging markets commentary on calls for actually you folks, the analysts. Internally, we have 3 different regions in the world; Americas, Europe and Asia, and we don't specifically monitor emerging markets anymore. We monitor specifically China, which we think is -- continued to perform well and is a very profitable large market for us. And if you qualify emerging markets like you speak, it's about 22% of our overall sales. So it's very much larger than for many of our peers. So that's why we don't focus on that. Thank you.

    有。我們在新興市場的表現相當不錯。今年新興市場大約成長 6.7%,接近 7%。我們在中國也超過 6%,這對我們來說很棒。我想強調的是,你們所說那種「新興市場像醫療器材那樣的資質/定義」並不適用於 Baxter。我們在那些市場已經深耕很久。所以對我們而言,中國是一個良好的成長市場,GDP 成長也不錯,這也代表我們有機會在那裡以及巴西、墨西哥、哥倫比亞(我認為這些可能是最突出的),還有東南亞,進行地理擴張並導入新的產品線。我們在電話會議上談新興市場,其實是為了你們各位分析師。在內部,我們把全球分成 3 個不同區域:美洲、歐洲與亞洲,我們不再特別監控「新興市場」這個分類。我們會特別監控中國,我們認為它——持續表現良好,對我們而言是一個非常獲利且規模很大的市場。如果用你們所說的新興市場定義來算,大約占我們整體銷售的 22%。所以這個比重確實比許多同業都大得多。這也是為什麼我們不把焦點放在那個分類上。謝謝。

  • Operator

    Operator

  • And our final question comes from the line of Joanne Wuensch of BMO Capital Markets.

    我們的最後一個問題來自 BMO 資本市場(BMO Capital Markets)的 Joanne Wuensch。

  • Joanne Karen Wuensch - MD & Research Analyst

    Joanne Karen Wuensch - MD & Research Analyst

  • Joe, big picture MedTech. You guys are probably closest to the ground of what's happening in the hospital as it relates to volume, price and flu. Can you just give us somewhat brief overview of what you're really seeing out there?

    Joe,從醫療科技(MedTech)的大方向來看。就醫院端正在發生的事情而言,特別是與量、價以及流感相關,你們大概是最貼近第一線的。你能否簡要概述一下你們實際看到的情況?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • We are projecting low single digits for hospital procedures and admissions in general. That's what we see in our -- when we connect the dots of our businesses. We also see a renewed interest in the capital investment from hospitals, at least one of the large hospital not-for-profit groups announced that they will revitalize plans for investment, and that is good for the market. And we see also, in general, consumption at a stable to slightly positive level. So it is, altogether, a unique situation for the country, for the U.S., specifically where we see the healthcare markets reacting well to new tax legislation and so forth. The flu season is clearly picking up a significant amount of steam. It's already high for all accounts. And there's some -- there's always a slight positive impact because a couple of our businesses and products are used for situations where the patient is in ICU with a distress and multiorgan failure. So there is a big cap for our business when there is a good flu season. Flu season is all-time high.

    我們預估醫院手術量與整體住院人次大致是低個位數成長。這是我們——在把各項業務線索串起來後所看到的情況。我們也看到醫院對資本投資的興趣再度升溫;至少有一家大型的非營利醫院集團宣布將重啟投資計畫,這對市場是好事。此外,我們也看到整體耗材使用量大致維持穩定到略為正向。因此整體而言,這對美國、特別是美國市場來說,是一個相當獨特的情況;我們看到醫療照護市場對新的稅改法案等因素反應良好。流感季顯然正在快速升溫。就各方觀察來看,目前已經處於高位。而且會有一些——通常會有些微的正面影響,因為我們有幾項業務與產品用於病患在加護病房(ICU)出現呼吸窘迫與多重器官衰竭等情況。所以當流感季很嚴重時,對我們的業務會有明顯的上限效益(cap)。流感季處於歷史新高。

  • Joanne Karen Wuensch - MD & Research Analyst

    Joanne Karen Wuensch - MD & Research Analyst

  • Okay. And then a follow-up, a more specific question. Every year, I feel like we start off with a relatively high cyclo competition headwind and then winnow it down throughout the year. Why is the $100 million the right number for 2018?

    好的。接著追問一個更具體的問題。每一年,我都覺得我們一開始面臨相對較高的環磷醯胺競爭逆風,然後在一年當中逐步縮小。為什麼1億美元是2018年合適的數字?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Because we do model quite extensively and very precisely the impact of 1 entrant, 2 entrants, 3 entrants, 4 entrants. We do this because as a matter of fact, we are, sometimes on the other hand, we're coming in as the second or the third entrant, so we know what the number is. So we have modeled, based on the number of applications out there for cyclophosphamide that, that is the impact. Now if people can't pull through, they don't have the regulatory capability, clearly, there's an upside for Baxter, and you guys we'll let you know as we give updates to our quarterly forecast and update guidance if we see that there's no entrant, we'll update and increase that if that's the case. As I always say, we're very transparent about cyclophosphamide, and it's always a positive for the company because more cash in our pocket. And it's a drug that is proven to many, not that easy to make. Cytotoxic drugs are very difficult to make, and Baxter has a state-of-the-art facility that is not only used by us, but used by many different pharmaceutical companies because of the difficulty of doing it. So the desire to do it is not -- that doesn't relate to the ability to do it and recently one potential manufacturer got 2 warning letters in their facility in India so they'll probably put a stop on their ability to produce. But there are others out there than we have modeled. So if they come to the market, we estimate it very precisely $100 million of impact.

    因為我們確實做了相當廣泛且非常精準的建模,來衡量1個競爭者、2個競爭者、3個競爭者、4個競爭者的影響。我們這麼做是因為事實上,有時候反過來我們也會成為第二個或第三個進入者,所以我們知道那個數字會是多少。因此,我們已根據目前市面上環磷醯胺的申請數量進行建模,這就是其影響。現在,如果有人無法順利推進、沒有法規能力,顯然對百特而言就是上行空間;各位,我們也會在每季更新預測與調整指引時告知你們最新情況;如果我們看到沒有新的進入者,我們會更新並在那種情況下上調。如我一向所說,我們對環磷醯胺非常透明,而這對公司總是正面的,因為我們口袋裡會有更多現金。而且這是一種已被證明對許多人而言並不那麼容易製造的藥物。細胞毒性藥物非常難製造,而百特擁有最先進的設施,不僅供我們使用,也因為製程困難而被許多不同的製藥公司使用。所以想做這件事的意願並不——那並不等同於有能力做到;而且最近有一家潛在製造商在其印度廠區收到了兩封警告信,因此他們的生產能力很可能會被迫停止。但我們已將其他可能的競爭者納入模型。因此,如果他們進入市場,我們非常精準地估計其影響為1億美元。

  • Operator

    Operator

  • And that concludes our question-and-answer session for today. Ladies and gentlemen, this does conclude today's conference call with Baxter International. Thank you for participating, and have a great day.

    以上為我們今天的問答環節。各位女士、先生,百特國際今天的電話會議到此結束。感謝各位參與,祝各位有美好的一天。